Sugi Predict

Sugi Predict / Compounds / SCHEMBL5348541

SCHEMBL5348541

SCHEMBL5348541

CCOC(=O)[C@H](CCc1ccccc1)OC(=O)[C@@H](N)CCCCNC(=O)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40
▸ NCOR2 Q9Y618 1/20 0.40
▸ ANPEP P15144 1/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP7 Q9UHL4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5349213 1.00 SMN1; SMN2 (0.41) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
SCHEMBL3369068 1.00 SMN1; SMN2 (0.41) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
SCHEMBL9022605 1.00 SMN1; SMN2 (0.41) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
SCHEMBL5353931 0.90 ANPEP (0.42) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
SCHEMBL3373748 0.90 ANPEP (0.42) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
SCHEMBL7276985 0.89 ANPEP (0.41) SMN1; SMN2POLBCYP1A2CYP2C9CYP2C19
Proline SCHEMBL7375209 0.88 ACE (0.38) CYP1A2CYP2C9CYP2C19HDAC3HDAC4
Proline SCHEMBL5823940 0.87 ACE (0.38) CYP1A2CYP2C9CYP2C19HDAC3HDAC4
SCHEMBL9856515 0.85 KMT2A (0.43) SMN1; SMN2POLBANPEPDPP8DPP7
SCHEMBL3368639 0.85 KMT2A (0.43) SMN1; SMN2POLBANPEPDPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253299-B2 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2007-08-07 — — US claimed
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2004-07-29 — — US claimed
EP-1405845-A1 METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE KANEKA CORPORATION (JP) 2004-04-07 — — EP claimed
US-7253299-B2 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2007-08-07 — — US disclosed
US-7253299-B2 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2007-08-07 — — US disclosed
US-20070093664-A1 Process for the production of lisinopril ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) 2007-04-26 — — US disclosed
US-20070093664-A1 Process for the production of lisinopril ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) 2007-04-26 — — US disclosed
EP-1513868-B1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL (TR) 2006-08-09 — — EP disclosed
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2004-07-29 — — US disclosed
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2004-07-29 — — US disclosed
EP-1405845-A1 METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE KANEKA CORPORATION (JP) 2004-04-07 — — EP disclosed
EP-1405845-A1 METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE KANEKA CORPORATION (JP) 2004-04-07 — — EP disclosed
JP-2003026644-A PURIFICATION PROCESS OF N2-[1(S)-ETHOXY-CARBONYL-3- PHENYLPROPYL]-N6-TRIFLUOROACETYL-L-LYSINE KANEGAFUCHI CHEM IND CO LTD 2003-01-29 — — JP disclosed
EP-0336368-B1 N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound KANEGAFUCHI CHEMICAL IND (JP) 1995-02-01 — — EP disclosed
EP-0239062-B1 N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-05-29 — — EP disclosed
EP-0336368-A2 N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1989-10-11 — — EP disclosed
EP-0239062-A2 N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-09-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KARS1, L3MBTL1, PKN2 SMN1; SMN2 1082/4885POLB 2107/4885CYP1A2 4231/4885
US-20070093664-A1 Process for the production of lisinopril ACE, LOX, AGT SMN1; SMN2 2164/4885POLB 574/4885CYP1A2 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.